COMPANY
Akura Medical
Akura Medical is listed on ClinicalTrials.gov as the lead sponsor of 3 studies; the most recently updated is “Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)” (no phase, suspended), in Pulmonary Embolism Acute. From public records Source · Oct 12, 2026
Funding and NIH signals
- SEC Form D raise Raised $51.45M (Form D filed Dec 3, 2025). SEC Form D 0000905148-25-004216 (Dec 3, 2025)
Evidence (1 event)
- Dec 3, 2025 · SEC Form D 0000905148-25-004216
Name of Issuer: Akura Medical, Inc.; CIK: 1902758; Address: Campbell, CA; Submission type: D; Filing date: 2025-12-03; Industry Group: Other Health Care; Date of First Sale: 2025-11-12; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 71999999; Total Amount Sold: 51449999; Federal exemptions: 06b
- Dec 3, 2025 · SEC Form D 0000905148-25-004216